Avecure Flexible Microwave Ablation Probe For Lung Nodules

Study summary

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAveCure 16 Gauge Flexible Microwave Ablation Probe

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 8, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Beth Israel Deaconess Medical Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: Beth Israel Deaconess Medical Center
Interventions being studied: Device: AveCure 16 Gauge Flexible Microwave Ablation Probe

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Early-stage or resectable→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
Resection/surgical candidate (lobectomy or greater)
Participants must be at least 22 years old and able to provide consent

Reasons someone may not be able to joinExclusion criteria

Subjects in whom flexible bronchoscopy is contraindicated
Target nodule \< 1.0 cm
Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
Pacemaker, implantable cardioverter, or another electronic implantable device
Patient cannot tolerate bronchoscopy
Patients with coagulopathy
Patients in other therapeutic lung cancer studies
Subject is pregnant or breastfeeding
COVID-19 positive patient at the time of procedure.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Beth Israel Deaconess Medical CenterBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 8, 2026. Always confirm current availability with the study team.

View original record ↗